Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N9-GP for treatment and prophylaxis of bleeding episodes in haemophilia B
2010-023069-24Phase 3
- Sponsor
- Novo Nordisk
- Start
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, single-blind trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoint: Incidence of inhibitory antibodies against factor IX.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2010-023069-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023069-24.